Portal de Periódicos da CAPES

Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma

2019; Massachusetts Medical Society; Volume: 380; Issue: 21 Linguagem: Inglês

10.1056/nejmoa1901963

1533-4406

Richard Beasley, Mark Holliday, Helen K. Reddel, Irene Braithwaite, Stefan Ebmeier, Robert J. Hancox, Tim Harrison, Claire Houghton, Karen Oldfield, Alberto Papi, Ian Pavord, Mathew Williams, Mark Weatherall,

Chronic Obstructive Pulmonary Disease (COPD) Research

In double-blind, placebo-controlled trials, budesonide–formoterol used on an as-needed basis resulted in a lower risk of severe exacerbation of asthma than as-needed use of a short-acting β2-agonist (SABA); the risk was similar to that of budesonide maintenance therapy plus as-needed SABA. The availability of data from clinical trials designed to better reflect clinical practice would be beneficial.